(Q47915365)

6 February 2018

title

The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer (English)

1 reference

6 February 2018

author name string

Leslie K Diaz

1

1 reference

6 February 2018

Rohit Gupta

2

1 reference

6 February 2018

Noman Kidwai

3

1 reference

6 February 2018

Nour Sneige

4

1 reference

6 February 2018

Elizabeth L Wiley

5

1 reference

6 February 2018

publication date

1 April 2004

1 reference

6 February 2018

Journal of Histochemistry and Cytochemistry

published in

1 reference

6 February 2018

volume

52

1 reference

6 February 2018

issue

4

1 reference

6 February 2018

page(s)

501-507

1 reference

6 February 2018

Evaluating HER2 amplification and overexpression in breast cancer.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Validation of tissue microarray technology in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Recommendations for HER2 testing in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

21 January 2018

Testing for HER2 status

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Tissue microarrays for high-throughput molecular profiling of tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

HER2 as a prognostic factor in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Tissue microarrays for rapid linking of molecular changes to clinical endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

First-line Herceptin monotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F002215540405200408

10.1177/002215540405200408

21 January 2018

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018